BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34895262)

  • 1. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
    Hu Y; Paris S; Barsoumian H; Abana CO; He K; Sezen D; Wasley M; Masrorpour F; Chen D; Yang L; Dunn JD; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
    J Nanobiotechnology; 2021 Dec; 19(1):416. PubMed ID: 34895262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
    Hu Y; Paris S; Bertolet G; Barsoumian HB; Wang Q; Da Silva J; Patel NB; Nguyen N; Doss DJ; Huang A; Hsu E; Leyton CSK; Voss TA; Masrorpour F; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
    Front Immunol; 2022; 13():1022011. PubMed ID: 36405757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
    Hu Y; Paris S; Barsoumian H; Abana CO; He K; Wasley M; Younes AI; Masrorpour F; Chen D; Yang L; Dunn JD; Zhang J; Gandhi S; Nguyen QN; Cortez MA; Welsh J
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):647-657. PubMed ID: 34242713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
    Hu Y; Paris S; Bertolet G; Barsoumian HB; He K; Sezen D; Chen D; Wasley M; Silva JD; Mitchell JA; Voss TA; Masrorpour F; Leyton CK; Yang L; Leuschner C; Puebla-Osorio N; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
    J Nanobiotechnology; 2022 Sep; 20(1):417. PubMed ID: 36123677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
    Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
    Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
    [No Abstract]   [Full Text] [Related]  

  • 8. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
    Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.
    Hartmann L; Osen W; Eichmüller OL; Kordaß T; Furkel J; Dickes E; Reid C; Debus J; Brons S; Abdollahi A; Moustafa M; Rieken S; Eichmüller SB
    Cancer Lett; 2022 Dec; 550():215928. PubMed ID: 36183858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor.
    Misaki S; Murata S; Shimoji M; Iwai T; Sihombing AM; Aoki K; Takahashi Y; Watanabe Y
    Jpn J Radiol; 2022 Dec; 40(12):1307-1315. PubMed ID: 35763240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
    Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
    Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
    Front Immunol; 2018; 9():2170. PubMed ID: 30294332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
    Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade.
    Moore C; Hsu CC; Chen WM; Chen BPC; Han C; Story M; Aguilera T; Pop LM; Hannan R; Fu YX; Saha D; Timmerman R
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1306-1316. PubMed ID: 33794306
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
    Front Immunol; 2020; 11():1610. PubMed ID: 32849544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
    Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
    Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
    Hu Y; Paris S; Sahoo N; Bertolet G; Wang Q; Wang Q; Barsoumian HB; Da Silva J; Huang A; Doss DJ; Pollock DP; Hsu E; Selene N; Leyton CSK; Voss TA; Masrorpour F; Ganjoo S; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
    JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37345658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
    Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.